Insulin but not IGF-I is required for the maintenance of the adipose phenotype in the adipogenic cell line 1246

Citation metadata

Date: Nov. 1999
Publisher: Springer
Document Type: Article
Length: 309 words

Document controls

Main content

Abstract :

Byline: Ginette Serrero (1), Nancy Lepak (1) Keywords: proliferation; adipose differentiation; adipocyte; adipocyte precursors; insulin; insulin-like growth factor I Abstract: The mouse adipogenic cell line 1246 which possesses both insulin and insulin-like growth factor I (IGF-I) receptors was used to investigate the role of IGF-I and insulin on the proliferation of adipocyte precursors and their differentiation into mature adipocytes. Results indicate that both insulin and IGF-I stimulate the proliferation of the 1246 adipocyte precursors with IGF-I being slightly more potent than insulin. Dose-response studies indicated that both polypeptides acted at physiological concentrations corresponding to binding to their own receptors. In contrast, comparison of insulin and IGF-I capacity to stimulate terminal adipose differentiation indicated that only insulin was active when added at physiological concentrations. IGF-I could not stimulate adipocyte differentiation except at supraphysiological concentrations (100 ng/ml and above) permitting its binding to the insulin receptors on 1246 cells. Time course study of expression of early and late markers of adipose differentiation indicated that the induction of markers such as adipose differentiation-related protein (ADRP), lipoprotein lipase (LPL) and fatty acid binding protein (FAB) took place even in the absence of insulin. However, the level of early and late differentiation markers decreased to a level below the one found in undifferentiated cells when cells had been maintained in the absence of insulin after differentiation had been initiated. These data indicate that although insulin is not necessary for the early onset of the adipose differentiation program, it is stringently required for the maintenance of the adipocyte phenotype and cannot be substituted by IGF-I. Author Affiliation: (1) Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy and Program of Oncology, Marlene and Stewart Greenebaum Cancer Center of the University of Maryland, 21201-1180, Baltimore, Maryland (2) Trudeau Institute, 12983, Saranac Lake, New York Article History: Registration Date: 18/05/1999 Received Date: 16/12/1998 Accepted Date: 03/05/1999

Source Citation

Source Citation   

Gale Document Number: GALE|A206213136